MedTrace Logo

The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes

NCT05566028 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2024-12-10

No results posted yet for this study

Summary

The purpose of this study is to prove that the group treated with D745 in combination added that the reduction of HbA1c superior to placebo treated group added in combination.

Conditions

Interventions

DRUG

D745 formulation I

QD for 24 weeks or 52 weeks(if extension study) with D150 and D759

DRUG

D745 formulation II

QD for 24 weeks or 52 weeks(if extension study) with D150 and D759

DRUG

D745 Placebo

QD for 24 weeks or 52 weeks(if extension study) with D150 and D759

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Youngmin Cho, M.D, Ph.D · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-12
Primary Completion
2024-01-10
Completion
2024-07-23

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05566028 on ClinicalTrials.gov